Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
242
resultados
Última actualización
15/04/2026 [08:05:00]
Resumen de: JP2026062733A
【課題】炎症性疾患の診断を支援可能なバイオマーカーとその使用方法。【解決手段】多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害のマーカーとして、対象からのサンプル中のインフラマソームの成分を検出するための組成物及び方法。多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害を有する対象について、予後を判定し、処置を指示し、且つ処置に対する反応をモニタリングするためにかかるインフラマソームマーカーを使用する方法も記載される。【選択図】図３２
Resumen de: JP2026510789A
本発明は、ＰＡＭの立体構造エピトープに対する少なくとも１つの結合剤を含むアッセイを使用して、体液又は組織試料中のＰＡＭ及び／又はそのアイソフォーム及び／又はその断片のレベルを決定するための方法、並びに診断目的のためのその使用を対象とする。【選択図】なし
Resumen de: WO2026074061A1
In the present invention provided is a method for classifying a subject as a high-risk for neurological or psychiatric disorder subject. The method is particularly useful when the neurological or psychiatric disorder is selected from the group containing schizophrenia, psychosis, mood disorder, depression (such as major depressive disorder), bipolar disorder, Alzheimer's disease, Parkinson disorder, and cognitive impairment. The present invention further relates to a biomarker kit comprising reagents for determining expression level of biomarkers for extracellular vesicles, brain-derived extracellular vesicles and biomarkers for mitochondrial and redox impairment, N-methyl-D-aspartate receptor pathway, and other pathways related to central nervous system disorders.
Resumen de: WO2026076419A1
Provided herein are, inter alia, methods and compositions for transfecting a brain cell (e.g., neuron). The methods for transfecting a brain cell provided herein including embodiments thereof include, for example, transfecting the brain cell with a viral vector encoding a potassium-selective light-sensitive protein (e.g., kalium channelrhodopsin). Also provided herein are, inter alia, methods of modulating a neural network of brain cells (e.g., neurons) by activating a potassium-selective channelrhodopsin with light. The methods and compositions provided herein are, inter alia, useful for treating neurological or psychiatric diseases or disorders (e.g., epilepsies, Parkinson's disease, Alzheimer's, etc.).
Resumen de: US20260098855A1
0000 The present invention provides methods, compositions, kits, and devices for detecting heavy metals in dried blood (e.g., dried blood spots). For example, the present invention provides: 1) dried blood spot paper that is detectably free of heavy metals and methods of preparing such paper using organic acid; 2) dried blood extraction solutions optimized for heavy metal detection (e.g., extraction solutions containing acetic acid and/or gold); 3) methods for estimating venous blood volume from dried blood mass; and 4) kits and kit components optimized for heavy metal detection in dried blood (e.g., kits with paper detectably free of heavy metals, heavy metal free skin wipes, metal free collection case, etc.).
Resumen de: US20260097094A1
0000 Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.
Resumen de: AU2024370445A1
The present invention provides a method for determining a biological age, mortality risk and/or probability of a healthy lifespan of a dog; said method comprising: a) determining a biological age, mortality risk and/or probability of a healthy lifespan of the dog using the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count; and b) determining a biological age, mortality risk and/or probability of a healthy lifespan for the dog using a DNA methylation profile from the dog.
Resumen de: US20260098305A1
Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.
Resumen de: US20260098868A1
A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.
Resumen de: US20260098080A1
0000 A protein comprising amino acid sequence of SEQ ID NO: 115, within which a segment of general formula Ih-mod GX<1>CX<1V>X<2>X<3>X<4>X<5 >is present where X<1 >is any of F, Y, L, P, Q, M, V, W, A, or T, X<1V >is R, or K, X<2 >is any of A, G, S, or T, X<3 >is any amino acid of the 17-set, where the 17-set comprises A, I, L, F, or Y, X<4 >is any of K, I, Q, R, H, S, F, M, N, L, or V, and X<5 >is any of R, V, I, K, M, Q, E, F, L, N, Y, D, S, H; and b) in position 34 of SEQ ID NO: 115 it contains an amino acid selected from the 34-set contains any amino acid of the 34-set, where the 34-set comprises Y, I, F, G, V and S, and use in pharmaceutical preparations, kits, screening procedures.
Resumen de: US20260098070A1
0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.
Resumen de: EP4721657A1
Die vorliegende Erfindung betrifft ein nicht-invasives Verfahren zur Bestimmung von Atemgasen aufweisend Schwefelwasserstoff, insbesondere zur Verwendung in der Medizin, Diagnose, Prädiktion, Risikostratifizierung und Therapiesteuerung von Erkrankungen, insbesondere Darmerkrankungen an Probanden, wobei durch Bakterien gebildete Gase in dem Ausatemgas bestimmt werden, wobei der Schwefelwasserstoff nicht nachteilig abgebaut wird.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: US20260092920A1
The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.
Resumen de: US20260091025A1
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.
Resumen de: US20260092926A1
0000 There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.
Resumen de: US20260094269A1
0000 Disclosed is a method for diagnosing a neurodegenerative disease in a subject. The method comprises obtaining from the subject a sample comprising at least one live blood cell, and optionally isolating at least one live blood cell from the sample. The method further comprises generating one or more multispectral or hyperspectral images of the at least one cell, and analysing spectral characteristics of autofluorescence from the at least one cell. Also disclosed is a system configured to aid in the detection or diagnosis of a neurodegenerative disease. Also disclosed is a method for selecting a subject for treatment for a neurodegenerative disease. Also disclosed is a method for monitoring the response of a subject to a therapeutic treatment for a neurodegenerative disease. Also disclosed is a protocol for monitoring the efficacy of a therapeutic treatment for a neurodegenerative disease.
Resumen de: US20260092110A1
0000 The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
Resumen de: US20260092326A1
Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.
Resumen de: WO2026071242A1
The present invention addresses the problem of providing: a nerve cell analysis method with which the localized amount of TDP-43 in nerve cells can be analyzed without labeling TDP-43 with a fluorescent tag or the like and without carrying out gene transfer; a kit for carrying out the nerve cell analysis method; and a screening method for a prophylactic and/or therapeutic agent for a neurodegenerative disease. The present invention provides a nerve cell analysis method involving: a staining step for immunofluorescent staining of nerve cells using an anti-TDP-43 antibody and an antibody that recognizes a stress granule marker; a cell region identification step for identifying the cytoplasm and nuclei of the nerve cells; and an analysis step for analyzing a TDP-43-derived fluorescence signal and a stress granule marker-derived fluorescence signal in the cytoplasm, and analyzing the localized amount of TDP-43 in the nerve cells on the basis of the presence or absence of colocalization of a granular TDP-43 signal and a granular stress granule marker signal in the cytoplasm.
Resumen de: US20260092917A1
The present invention relates to a method for determining distinguishing parameters of a neuro-inflammatory disease, said method comprising (a) obtaining parameters from a group of samples, wherein said group of samples comprises at least (i) a first subgroup of samples, and (ii) a second subgroup of samples, and (b) determining distinguishing parameters of the obtained parameters in step (a) at least between said first subgroup of samples and said second subgroup of samples by conducting analytical determination. Further, the present invention relates to a set of distinguishing parameters as well as distinct uses of such sets. Additionally, the present invention relates to a method for determining a subtype of a neuro-inflammatory autoimmune disease in a subject.
Resumen de: US20260091079A1
0000 Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
Resumen de: WO2026071006A1
The present invention is such that a test substance derived from an amyloid-β precursor protein in a blood sample, a substance that binds to the test substance, and a buffer solution are brought into contact for 6 minutes or less. The buffer solution contains a buffering agent where the concentration at the time of contact is 25 mM or more, and is such that the pH is 3.5 to 9.0. A signal derived from the binding between the test substance and the substance binding to the test substance is measured.
Nº publicación: WO2026067804A1 02/04/2026
Solicitante:
SALUBRIS CHENGDU BIOTECH CO LTD [CN]
SHENZHEN SALUBRIS PHARMACEUTICALS CO LTD [CN]
SALUBRIS SUZHOU PHARMACEUTICALS CO LTD [CN]
\u4FE1\u7ACB\u6CF0\uFF08\u6210\u90FD\uFF09\u751F\u7269\u6280\u672F\u6709\u9650\u516C\u53F8
\u6DF1\u5733\u4FE1\u7ACB\u6CF0\u836F\u4E1A\u80A1\u4EFD\u6709\u9650\u516C\u53F8
\u4FE1\u7ACB\u6CF0\uFF08\u82CF\u5DDE\uFF09\u836F\u4E1A\u6709\u9650\u516C\u53F8
Resumen de: WO2026067804A1
Provided in the present invention is an anti-APRIL antibody or an antigen-binding fragment thereof. Further provided are a polynucleotide encoding the antibody, a vector and host cell for expressing the antibody, a pharmaceutical composition containing the antibody, a method for treating APRIL-associated diseases using the antibody, and the pharmaceutical use thereof.
BOPI
Sede Electrónica
